Scarica l'app Stockscreener
43.39
0.48%
-0.2216
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com South Africa
BMY Collaboration Advances ALS Treatment Development - GuruFocus
$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan
Kardigan raises $254M to test cardio drugs from Sanofi, BMS and Ionis - Endpoints News
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl
Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Yahoo Finance
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
Bristol Myers Faces Legacy Headwinds But Banks On Its Pipeline - Finimize
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight - GlobeNewswire Inc.
Bispecifics in Oncology Market Statistics Expected to Experience Major Growth by 2040, According to DelveInsight | AstraZeneca, I-MAB Biopharm, BioNTech, Bristol Myers Squibb - Barchart.com
Trend analysis for Bristol Myers Squibb Company this weekJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration - BioSpace
Mark Cuban’s Pharmacy Targets Drug Pricing Reform as AstraZeneca Invests $4.5 Billion in Virginia and Bristol Myers Squibb Acquires Orbital Therapeutics for $1.5 Billion - geneonline.com
Stock Looks Undervalued As Bristol Myers Buys Orbital Therapeutics (NYSE:BMY) - Seeking Alpha
2025 Showcasing Progress of Oncology Portfolio Across Diverse Tumor Types - Business Wire
Bristol Myers (BMY) Triggers Milestone Payment with SystImmune C - GuruFocus
Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 20% Potential Upside Amidst a Robust Dividend Yield - DirectorsTalk Interviews
SystImmune receives $250 million milestone payment from Bristol Myers Squibb - Investing.com
Covington aids Bristol Myers Squibb on Orbital Therapeutics acquisition - ICLG.com
Notable healthcare headlines for the week: Novo Nordisk, Bristol Myers Squibb and J&J in focus - Seeking Alpha
Bristol-Myers Squibb (BMY): Exploring Valuation After Recent Share Price Declines - simplywall.st
Bristol Myers Squibb: Value Emerges From Distress - Seeking Alpha
Bristol Myers Squibb’s Alzheimer’s Drug, BMS-986446, Granted FDA Fast Track Status - Yahoo Finance
Conning Inc. Has $33.17 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Fourpath Capital Management LLC Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
CAR Ts for autoimmune ramp up: BMS buying Orbital for $1.5B - BioWorld MedTech
BMS expands CAR-T portfolio with $1.5bn Orbital buyout - Pharmaceutical Technology
Bristol Myers to buy Cambridge startup Orbital Therapeutics, building out cell therapy pipeline - The Boston Globe
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push | Business Information & News | FE - Westlaw Today
What's Going On With Bristol Myers Squibb Stock Friday?Bristol-Myers Squibb (NYSE:BMY) - Benzinga
Bristol Myers Expands Cell Therapy Portfolio With Orbital Therapeutics Acquisition - Sahm
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Acquisition - GuruFocus
Chart based analysis of Bristol Myers Squibb Company trendsEntry Point & Fast Moving Market Watchlists - newser.com
Bristol Myers Squibb buys Cambridge biotech for $1.5B - The Business Journals
BMS latest to enter in vivo CAR-T field with $1.5B Orbital buy - FirstWord Pharma
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push - Reuters
Bristol Myers Squibb To Acquire Orbital Therapeutics - citybiz
Bristol Myers makes $1.5B bid for Orbital Therapeutics - The Pharma Letter
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Bristol Myers buys Orbital Therapeutics for $1.5 billion in cell therapy push By Reuters - Investing.com
Bristol Myers (BMY) to Acquire Orbital Therapeutics in $1.5 Bill - GuruFocus
Bristol Myers Squibb (BMY) Expands with Orbital Therapeutics Acq - GuruFocus
Bristol Myers Squibb to acquire Orbital for $1.5B - NJBIZ
Bristol Myers Squibb to acquire Orbital Therapeutics for $1.5 billion - Investing.com
$1.5B deal: Bristol Myers Squibb acquires Orbital, gaining OTX-201 and RNA in vivo CAR T platform - Stock Titan
Bristol-Myers Squibb Co. v. Matrix Laboratories Ltd. - Law.com
Bristol Myers Squibb and TV Host Gail Simmons Tackle Stigma in Schizophrenia with New Initiative Spotlighting the Power of Support and Connection – Company AnnouncementFT.com - Financial Times
Blair William & Co. IL Sells 222,590 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Sold by Vontobel Holding Ltd. - MarketBeat
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term - Yahoo Finance
Abel Hall LLC Has $444,000 Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Shell Asset Management Co. Raises Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Kingswood Wealth Advisors LLC - MarketBeat
Pharmaceutical research and development pipeline - Bristol Myers Squibb
Cell Therapy Market Set for Dynamic Growth with Key Players Bristol Myers Squibb Company, Amgen Inc. - industrytoday.co.uk
2.01%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):